IS7614A - Píperidín afleiður og notkun þeirra sem val-hindrar af MIP-1 alfa sem bindast CCR 1 viðtaka hans - Google Patents

Píperidín afleiður og notkun þeirra sem val-hindrar af MIP-1 alfa sem bindast CCR 1 viðtaka hans

Info

Publication number
IS7614A
IS7614A IS7614A IS7614A IS7614A IS 7614 A IS7614 A IS 7614A IS 7614 A IS7614 A IS 7614A IS 7614 A IS7614 A IS 7614A IS 7614 A IS7614 A IS 7614A
Authority
IS
Iceland
Prior art keywords
ccr
mip
receptor
selective inhibitor
piperidine derivatives
Prior art date
Application number
IS7614A
Other languages
English (en)
Inventor
Cook Blumberg Laura
Frank Brown Matthew
Merrill Hayward Matthew
Stanley Poss Christopher
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS7614A publication Critical patent/IS7614A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS7614A 2002-07-18 2004-12-23 Píperidín afleiður og notkun þeirra sem val-hindrar af MIP-1 alfa sem bindast CCR 1 viðtaka hans IS7614A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39710802P 2002-07-18 2002-07-18
PCT/IB2003/002876 WO2004009550A1 (en) 2002-07-18 2003-07-07 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1

Publications (1)

Publication Number Publication Date
IS7614A true IS7614A (is) 2004-12-23

Family

ID=30770997

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7614A IS7614A (is) 2002-07-18 2004-12-23 Píperidín afleiður og notkun þeirra sem val-hindrar af MIP-1 alfa sem bindast CCR 1 viðtaka hans

Country Status (24)

Country Link
US (1) US20040063759A1 (is)
EP (1) EP1534677A1 (is)
JP (1) JP2005537279A (is)
KR (1) KR20050021497A (is)
CN (1) CN1668592A (is)
AP (1) AP2005003200A0 (is)
AR (1) AR040583A1 (is)
AU (1) AU2003242941A1 (is)
BR (1) BR0312946A (is)
CA (1) CA2492651A1 (is)
EC (1) ECSP055547A (is)
HN (1) HN2003000222A (is)
IL (1) IL166010A0 (is)
IS (1) IS7614A (is)
MA (1) MA27326A1 (is)
MX (1) MXPA05000380A (is)
OA (1) OA12885A (is)
PA (1) PA8575901A1 (is)
PE (1) PE20040666A1 (is)
TN (1) TNSN05014A1 (is)
TW (1) TW200402416A (is)
UY (1) UY27897A1 (is)
WO (1) WO2004009550A1 (is)
ZA (1) ZA200500067B (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399790B2 (en) 2001-02-28 2008-07-15 Konowalchuk Thomas W Virucidal compositions
US7493363B2 (en) 2001-09-19 2009-02-17 Microsoft Corporation Peer-to-peer group management and method for maintaining peer-to-peer graphs
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
MXPA04012393A (es) 2002-06-12 2005-06-17 Chemocentryx Derivados de piperazina 1-aril-4-substituidos para utilizar como antagonistas ccr1 para tratamiento de inflamacion y desordenes inmunes.
CA2492110A1 (en) * 2002-07-18 2004-01-29 Pfizer Products Inc. Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor
US8261062B2 (en) 2003-03-27 2012-09-04 Microsoft Corporation Non-cryptographic addressing
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
CN1950082B (zh) 2004-03-03 2013-02-06 凯莫森特里克斯股份有限公司 双环和桥连的含氮杂环化物
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7929689B2 (en) 2004-06-30 2011-04-19 Microsoft Corporation Call signs
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
US7620902B2 (en) 2005-04-20 2009-11-17 Microsoft Corporation Collaboration spaces
US7617281B2 (en) 2005-04-25 2009-11-10 Microsoft Corporation System and method for collaboration with serverless presence
US7660851B2 (en) 2005-07-06 2010-02-09 Microsoft Corporation Meetings near me
MY150098A (en) 2005-07-26 2013-11-29 Glaxo Group Ltd Benzylpiperazine derivates and their medical use
WO2007044885A2 (en) 2005-10-11 2007-04-19 Chemocentryx, Inc. Piperidine derivatives and methods of use
US8069208B2 (en) 2006-04-21 2011-11-29 Microsoft Corporation Peer-to-peer buddy request and response
US8086842B2 (en) 2006-04-21 2011-12-27 Microsoft Corporation Peer-to-peer contact exchange
EP2202223B1 (en) * 2007-10-18 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound as blood rbp4 lowering agent
US20100168080A1 (en) * 2008-12-17 2010-07-01 Khamrai Uttam Novel compounds useful as cc chemokine receptor ligands
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (is) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
ES2250132T3 (es) * 1999-05-18 2006-04-16 Teijin Limited Remedios preventivos para enfermedades asociadas a quimioquinas.
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
ATE408611T1 (de) * 2001-07-24 2008-10-15 Richter Gedeon Nyrt Piperidine als nmda-rezeptorantagonisten

Also Published As

Publication number Publication date
AR040583A1 (es) 2005-04-13
HN2003000222A (es) 2004-11-23
PE20040666A1 (es) 2004-09-25
IL166010A0 (en) 2006-01-15
ZA200500067B (en) 2005-11-02
US20040063759A1 (en) 2004-04-01
UY27897A1 (es) 2004-02-27
AU2003242941A1 (en) 2004-02-09
MA27326A1 (fr) 2005-05-02
WO2004009550A1 (en) 2004-01-29
EP1534677A1 (en) 2005-06-01
BR0312946A (pt) 2005-07-12
TNSN05014A1 (fr) 2007-05-14
CA2492651A1 (en) 2004-01-29
AP2005003200A0 (en) 2005-03-31
MXPA05000380A (es) 2005-03-31
KR20050021497A (ko) 2005-03-07
ECSP055547A (es) 2005-03-10
PA8575901A1 (es) 2004-07-20
JP2005537279A (ja) 2005-12-08
TW200402416A (en) 2004-02-16
CN1668592A (zh) 2005-09-14
OA12885A (en) 2006-09-15

Similar Documents

Publication Publication Date Title
IS7434A (is) N-amínóasetýl-pýrrólídín-2-karbónítríl og notkun þeirra sem DDP-IV tálma
IS6855A (is) Benzamidazol og Pyrimidazol afleiður sem tengihópar við GABA viðtaka
EP1510210A4 (en) IMMUNITY-CONTAINING PROTEIN KINASE HEMMER
DK1170288T3 (da) Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
NO994101D0 (no) Heteroaryl-heksansyreamid-derivater, deres fremstilling og deres anvendelse som selektive inhibitorer for MIP-1-<alfa>-binding til dens CCR 1-reseptor
DK1202941T3 (da) Gipssammensætninger og beslægtede fremgangsmåder
IL166010A0 (en) Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1
DK1390014T3 (da) Sammensætning til anvendelse i en fremgangsmåde til behandling af hyperplasi
DE60310442D1 (de) Zusatzstoff zum feuchtigkeitsbeständigmachen einer gipsplatte
DE60109943D1 (de) Inhibitoren der durch alpha 4 vermittelten zelladhäsion
DE60311148D1 (de) Acrylat- bindemittel
IS8070A (is) Afleiður af píperidínýl- og píperasínýl-alkýl karbamötum, framleiðsluaðferðir þeirra og notkun í meðferðarfræði
NO20025123L (no) Vann-silisiumoksyd-suspensjoner for bruk i brönnsement
NO20032490L (no) Substituerte 2-anilin-benzimidazoler og deres anvendelse som NHE-inhibitorer
IL169336A0 (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
DK2305689T3 (da) Syntese af naturligt forekommende ecteinascidiner og relateredeforbindelser
IS6219A (is) Amínóþíazól afleiður og notkun þeirra sem CRF viðtaka bindlar
NO20044106L (no) Omkonstruerte baculoviruser og anvendelse derav
NO20043799L (no) 2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister
EP1768691A4 (en) AEQUORIN-CONTAINING COMPOSITIONS AND METHOD FOR THE APPLICATION THEREOF
DE60335065D1 (de) Polymermodifizierte Gipszusammensetzung
EP1811839A4 (en) METHOD AND COMPOSITIONS IN CONNECTION WITH ESCULENTOSIDE A
AU2003244978A8 (en) Methods to identify anti-tumoral agents inhibiting rasgap / aurora kinase interactions
DK1608381T3 (da) En sammensætnings nye terapeutiske anvendelse
SE0202115D0 (sv) Use of a composition